H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $36 from $35 and keeps a Buy rating on the shares following the Q4 report. The firm sees clinical data catalysts in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.